Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug
Phase I Shows Promise, But ION449 Must Catch Up With Inclisiran
Executive Summary
Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.
You may also be interested in...
AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval
Timing means full EU approval could coincide with US FDA authorization later this year.